RM-MET / Metabolic and incretin signalling
Liraglutide
Also known as: GLP-1 analog
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Liraglutide is a modified GLP-1 analog with a fatty-acid side chain that extends exposure relative to native GLP-1. It is distinct from semaglutide, exenatide and dual- or triple-receptor agonists.
Evidence position
FDA-labeled comparators and large human trials support Grade A for the molecule in those finished products.
What the record does not establish
Approval of a labeled product does not authenticate or qualify material from another source. Exact identity, strength, purity and microbiological quality remain lot-level questions.
Sources
- 01Liraglutide injection prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. finished-product label and initial approval history
- Does not show
- Describes a regulated finished product, not separately sourced research material
- 02Liraglutide and cardiovascular outcomes in type 2 diabetesPubMed
- Shows
- Large randomized human outcome trial
- Does not show
- Finished-drug evidence; not a lot-quality record
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Liraglutide
- CID
- 16134956
- Formula
- C172H265N43O51
- Mass
- 3751
PUBMED / FOUND RECORDS
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.The New England journal of medicine / 2016 Jul 28PMID 27295427 / DOI 10.1056/NEJMoa1603827
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.The Journal of clinical investigation / 2014 OctPMID 25202980 / DOI 10.1172/JCI75276
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.Molecular medicine (Cambridge, Mass.) / 2023 Sep 28PMID 37770820 / DOI 10.1186/s10020-023-00721-7
- Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.Advanced science (Weinheim, Baden-Wurttemberg, Germany) / 2024 OctPMID 39159301 / DOI 10.1002/advs.202405987
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.JAMA / 2015 Aug 18PMID 26284720 / DOI 10.1001/jama.2015.9676
CLINICALTRIALS.GOV / FOUND RECORDS
- Improving Beta Cell Function in Mexican American Women With PrediabetesCOMPLETED / PHASE4 / Ohio State UniversityNCT02488057 / DIRECT intervention MATCH: Liraglutide
- Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 DiabetesCOMPLETED / PHASE2 / Novo Nordisk A/SNCT01511172 / DIRECT intervention MATCH: Liraglutide
- Clinical Study on the Improvement of Diabetic Neuropathic Pain by LiraglutideUNKNOWN / NA / Fudan UniversityNCT04137328 / DIRECT intervention MATCH: Liraglutide
- Treatment of Hypoglycemia Following Gastric Bypass SurgeryCOMPLETED / PHASE4 / Zealand University HospitalNCT02527993 / DIRECT intervention MATCH: Liraglutide
- Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesCOMPLETED / PHASE3 / AstraZenecaNCT01029886 / DIRECT intervention MATCH: Liraglutide